The results of these retrospective analyses did not reach statistical significance and were insufficiently powered to conclude whether or not the BRAF V600E mutation is a biomarker of primary resistance to anti-EGFR agents in CRC [ 39 - 43 ].
1
—
—
The results of these retrospective analyses did not reach statistical significance and were insufficiently powered to conclude whether or not the BRAF V600E mutation is a biomarker of primary resistance to anti-EGFR agents in CRC [ 39 - 43 ].